PBGENE-HBV is designed to potentially cure chronic hepatitis B by eliminating the root cause of the virus. The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an ...

Chronic HBV was associated with increased risk for adverse COVID-19 outcomes, but the risk was lower among coinfected patients vaccinated against COVID-19.

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the acceptance of five abstracts, including a late-breaking study, for ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the ...

Hepatitis D virus (HDV) infects the liver and causes severe inflammation. According to WHO estimates, 12 million people ...